医师诊断的哮喘和/或慢阻肺在组内与组间的异质性:NOVELTY队列
按医师诊断和严重程度分层后,症状、生活质量和肺功能在哮喘、哮喘+慢阻肺和慢阻肺之间显示显著异质性与重叠。医师严重程度分级不能很好区分可能具有特定风险和治疗意义的临床表型。
要点
- 医师诊断的哮喘、哮喘+慢阻肺和慢阻肺之间症状、生活质量和肺功能存在显著异质性与重叠。
- 轻度哮喘和轻度慢阻肺患者中仍有相当比例过去12个月发生过至少1次急性加重。
- 用药记录提示相对严重程度存在治疗不足和治疗过度,血中性粒细胞计数随严重程度增加。
核心结论
- 医师诊断和严重程度分组在哮喘和/或慢阻肺患者中存在显著组内异质性和组间重叠。
- 当前临床实践中的诊断和严重程度分类不能很好区分可能具有特定风险和治疗意义的临床表型。
研究设计与样本
- NOVELTY是一项全球、3年前瞻性观察研究,纳入来自真实临床实践的哮喘和/或慢阻肺患者。
- 采用序数逻辑回归分析评估与医师评估严重程度相关的因素。
主要发现
- 哮喘、哮喘+慢阻肺和慢阻肺患者中,支气管舒张后FEV1/FVC低于正常下限的比例分别为23%、62%和64%。
- 症状和急性加重随医师评估严重程度增加而增加,且在哮喘+慢阻肺中更高。
- 24.3%的轻度哮喘患者和20.4%的轻度慢阻肺患者在过去12个月内经历过至少1次急性加重。
- 血嗜酸性粒细胞计数在不同诊断和严重程度组间变化不大,但血中性粒细胞计数在所有诊断中随严重程度增加。
关键数值与推荐
- 支气管舒张后FEV1/FVC低于正常下限的比例:哮喘23%,哮喘+慢阻肺62%,慢阻肺64%。
- 过去12个月内至少1次急性加重的比例:轻度哮喘24.3%,轻度慢阻肺20.4%。
临床怎么用
- 临床中应认识到哮喘和慢阻肺诊断及严重程度分组存在显著异质性,不能仅凭医师诊断和严重程度分级判断风险。
- 轻度哮喘和轻度慢阻肺患者仍可能发生急性加重,需关注其急性加重史。
- 用药记录提示可能存在治疗不足或过度治疗,应结合严重程度和表型优化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies of asthma and chronic obstructive pulmonary disease (COPD) typically focus on these diagnoses separately, limiting understanding of disease mechanisms and treatment options. NOVELTY is a global, 3-year, prospective observational study of patients with asthma and/or COPD from real-world clinical practice. We investigated heterogeneity and overlap by diagnosis and severity in this cohort. METHODS: Patients with physician-assigned asthma, COPD or both (asthma+COPD) were enrolled, and stratified by diagnosis and severity. Baseline characteristics were reported descriptively by physician-assigned diagnosis and/or severity. Factors associated with physician-assessed severity were evaluated using ordinal logistic regression analysis. RESULTS: Of 11 243 patients, 5940 (52.8%) had physician-assigned asthma, 1396 (12.4%) had asthma+COPD and 3907 (34.8%) had COPD; almost half were from primary care. Symptoms, health-related quality of life and spirometry showed substantial heterogeneity and overlap between asthma, asthma+COPD and COPD, with 23%, 62% and 64% of patients, respectively, having a ratio of post-bronchodilator forced expiratory volume in 1 s to forced vital capacity below the lower limit of normal. Symptoms and exacerbations increased with greater physician-assessed severity and were higher in asthma+COPD. However, 24.3% with mild asthma and 20.4% with mild COPD had experienced ≥1 exacerbation in the past 12 months. Medication records suggested both under-treatment and over-treatment relative to severity. Blood eosinophil counts varied little across diagnosis and severity groups, but blood neutrophil counts increased with severity across all diagnoses. CONCLUSION: This analysis demonstrates marked heterogeneity within, and overlap between, physician-assigned diagnosis and severity groups in patients with asthma and/or COPD. Current diagnostic and severity classifications in clinical practice poorly differentiate between clinical phenotypes that may have specific risks and treatment implications.
引用
- Reddel HK, Vestbo J, Agustí A, et al. Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. Eur Respir J. 2021. PMID: 33632799. doi:10.1183/13993003.03927-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。